Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 4/20 | 0.35 |
| ▸ | FLT3 | P36888 | 3/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.35 |
| ▸ | GAS6 | Q14393 | 3/20 | 0.35 |
| ▸ | KDR | P35968 | 4/20 | 0.34 |
| ▸ | AXL | P30530 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PLK1 | P53350 | 2/20 | 0.31 |
| ▸ | INSR | P06213 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2804670 | 0.88 | KDM4E (0.40) | MERTKFLT3TYRO3GAS6KDR | |
| SCHEMBL2806912 | 0.87 | HTR7 (0.36) | KDRALDH1A1PLK1INSR | |
| SCHEMBL13273524 | 0.82 | FGFR1 (0.40) | MERTKFLT3TYRO3GAS6KDR | |
| SCHEMBL2804238 | 0.82 | TRIM58 (0.36) | MERTKFLT3TYRO3GAS6KDR | |
| SCHEMBL2803960 | 0.81 | KDR (0.37) | MERTKKDRKDM4EALDH1A1GAA | |
| SCHEMBL2804032 | 0.81 | HPGD (0.40) | MERTKFLT3TYRO3GAS6KDR | |
| SCHEMBL2804916 | 0.81 | CASR (0.40) | KDRPLK1INSR | |
| SCHEMBL2806805 | 0.80 | KDM4E (0.34) | MERTKFLT3TYRO3GAS6KDR | |
| SCHEMBL2804601 | 0.80 | CCNA2 (0.39) | MERTKFLT3TYRO3GAS6KDM4E | |
| SCHEMBL2802006 | 0.79 | HDAC3 (0.42) | TYRO3KDRKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379506-B1 | SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F]ISOQUINOLIN-2-AMINE COMPOUNDS | ARQULE INC (US) | 2015-09-02 | — | — | EP | disclosed |
| EP-2379506-B1 | SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F]ISOQUINOLIN-2-AMINE COMPOUNDS | ARQULE INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-8357694-B2 | Substituted 5,6-dihydro-6-phenylbenzo[F]isoquinolin-2-amine compounds | ARQULE, INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-8357694-B2 | Substituted 5,6-dihydro-6-phenylbenzo[F]isoquinolin-2-amine compounds | ARQULE, INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-8357694-B2 | Substituted 5,6-dihydro-6-phenylbenzo[F]isoquinolin-2-amine compounds | ARQULE, INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-20100239525-A1 | SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F]ISOQUINOLIN-2-AMINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2010078421-A1 | SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F] ISOQUINOLIN-2-AMINE COMPOUNDS | ARQULE, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239525-A1 | SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F]ISOQUINOLIN-2-AMINE COMPOUNDS | NQO1, DPYD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MERTK 3268/4885FLT3 972/4885TYRO3 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.